Top

Prithviraj Bose, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Bose

After obtaining his medical degree in 2001 from the University of Calcutta in his hometown of Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose began a residency in general medicine at the Institute of Post-Graduate Medical Education and Research in Kolkata, which he left in early 2004 to move to the United States. He then completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington in 2005, and residency at the Henry Ford Hospital in Detroit, Michigan in 2007, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma from 2017 through 2010. Dr. Bose became American Board of Internal Medicine-certified in hematology and medical oncology in 2010.

He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center between July 2010 and January 2015. At VCU, Dr. Bose took care of patients with diverse hematologic malignancies and teamed up with noted translational scientist, Steven Grant, to design early phase clinical trials of novel, targeted drug combinations in AML.

In the Department of Leukemia at The University of Texas MD Anderson Cancer Center, which he joined in early 2015, Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He works closely with Dr. Srdan Verstovsek, chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis. He has presented his research at international conferences and regularly speaks on MPN topics. Dr. Bose’s other area of interest is chronic lymphocytic leukemia (CLL). His clinical practice consists largely of patients with MPNs or CLL, although he also treats many patients with MDS, CML and acute leukemias.

Dr. Bose sits on the MPN panel of the National Comprehensive Cancer Network. His work has appeared in leading peer-reviewed journals such as The New England Journal of Medicine, Blood, and Cancer Cell, as well as in Williams’ Hematology. Dr. Bose was previously editor-in-chief of Drug Target Insights, and is currently on the editorial board of Hematology. In 2011, Dr. Bose, then a first-year faculty member at Virginia Commonwealth University, was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. Now a naturalized US citizen, Dr. Bose was granted permanent residence in the United States in 2013 in the select “outstanding researcher” (first preference) category.

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001	Calcutta Medical College, University of Calcutta, Kolkata, IN, Medicine, MBBS

Postgraduate Training

2007-2010	Clinical Fellowship, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
2005-2007	Clinical Residency, Internal Medicine, Henry Ford Hospital, Detroit, Michigan
2004-2005	Clinical Internship, Internal Medicine, Internal Medicine Residency Spokane, Spokane, Washington
2003-2004	Clinical Residency, General Medicine, Institute of Post Graduate Medical Education and Research, Kolkata

Board Certifications

2010	American Board of Internal Medicine - Medical Oncology
2010	American Board of Internal Medicine - Hematology
2007	American Board of Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 2017 - 2023

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017

Assistant Professor, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, 2010 - 2015

Other Appointments/Responsibilities

Member, MPN, MLNEo and SM panels, National Comprehensive Cancer Network, Plymouth Meeting, PA, 2018 - 2023

Member, Protocol Review and Monitoring Committee, VCU Massey Cancer Center, Richmond, VA, 2013 - 2015

ER Physician, Oklahoma City VA Medical Center, Oklahoma City, OK, 2009 - 2010

Institutional Committee Activities

Member, Transfusion and Patient Blood Management Committee, 2021 - Present

Member, Readmissions Review Committee, 2020 - Present

Member, Scientific Review Committee (CRC) # 4, 2016 - 2023

Honors & Awards

2020	Waun Ki Hong Award: Excellence in Team Science, UT MD Anderson Cancer Center
2011	Physician's Recognition Award with Commendation, American Medical Association
2011	Clinical Research Training Institute, American Society of Hematology

Professional Memberships

Indian Doctors Association of Houston

2016 - Present

Society of Hematologic Oncology

2015 - Present

Southwest Oncology Group

2015 - Present

Harris County Medical Society

2015 - Present

Texas Medical Association

2015 - Present

American Association of Physicians of Indian Origin

2011 - Present

Indo American Cancer Association

2010 - Present

American Society of Clinical Oncology

2007 - Present

American Society of Hematology

2007 - Present

Selected Publications

Peer-Reviewed Articles

Fiskus, WC, Mill, CP, Bose, P, Masarova, L, Pemmaraju, N, Dunbar, A, Birdwell, C, Davis, JA, Das, K, Hou, H, Manshouri, T, Jain, A, Malovannaya, A, Philip, K, Alhamadani, N, Matthews, A, Lin, K, Flores, L, Loghavi, S, DiNardo, C, Su, X, Rampal, R, Bhalla, K. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2025. e-Pub 2025. PMID: 39561280.
Mughal, TI, Mascarenhas, J, Rampal, R, Bose, P, Lion, T, Ajufo, HO, Yacoub, A, Meshinchi, S, Masarova, L, Mesa, RA, Jamieson, C, Barbui, T, Saglio, G, van Etten, RA. Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms. Hematological Oncology 43(1), 2025. e-Pub 2025. PMID: 39825826.
Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
Gagelmann N, Bose P, Gupta V, McLornan DP, Vachhani P, Al-Ali HK, Ali H, Treskes P, Buckley S, Roman-Torres K, Scott B. Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. Clin Lymphoma Myeloma Leuk 24(11):796-803, 2024. e-Pub 2024. PMID: 39034203.
Kim DH, Jia F, Patel KP, Bose P, Wang SA, Bueso-Ramos C, Ok CY. Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow. Clin Lymphoma Myeloma Leuk 24(11):e878-e882, 2024. e-Pub 2024. PMID: 39107203.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison CN, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kröger N, Kuykendall AT, Loscocco GG, Mascarenhas JO, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani AD, Patel AA, Pemmaraju N, Rambaldi A, Rampal RK, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi AM, Barbui T. Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood 144(17):1813-1820, 2024. e-Pub 2024. PMID: 39116296.
Gerds AT, Harrison CN, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji RS, Bose P, Kremyanskaya M, Mead A, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC MD, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Advances 8(17):4511-4522, 2024. e-Pub 2024. PMID: 38820422.
Bose P. Momelotinib for the treatment of myelofibrosis. Blood 144(7):708-713, 2024. e-Pub 2024. PMID: 38958484.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Mascarenhas J, Mathews V, Passamonti F, Harrison C. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group. Leukemia 38(8):1831-1838, 2024. e-Pub 2024.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol 99(7):1434-1436, 2024. e-Pub 2024. PMID: 38613831.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. Haematologica 109(6):1977-1983, 2024. e-Pub 2024. PMID: 38268448.
Nwogbo OV, Fang H, Wang W, Xu J, Miranda RN, Bose P, Ok CY, Jorgensen JL, Medeiros LJ, Wang SA. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. Am J Clin Pathol 161(6):598-608, 2024. e-Pub 2024. PMID: 38372648.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Hunter AM, Bose P. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother 25(10):1391-1404, 2024. e-Pub 2024. PMID: 39067001.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Moving toward disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. e-Pub 2023. PMID: 37729609.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 7(19):5835-5842, 2023. e-Pub 2023. PMID: 37552106.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
Bose P, Kuykendall AT, Miller C, Kurtin S, Farina K, Harting DM, Mascarenhas JO, Mesa RA. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opinion on Pharmacotherapy 24(9):1091-1100, 2023. e-Pub 2023. PMID: 37163478.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol 146(6):522-529, 2023. e-Pub 2023. PMID: 37699357.
Reiter, A, Schwaab, J, DeAngelo, DJ, Gotlib, J, Deininger, M, Pettit, K, Alvarez-Twose, I, Vannucchi, AM, Panse, J, Platzbecker, U, Hermine, O, Dybedal, I, Lin, HM, Rylova, SN, Ehlert, K, Dimitrijevic, S, Radia, D, Drummond, MW, Hexner, E, Bose, P, Robinson, W, Hunter, AM, Tashi, T, Heaney, ML, Mesa, RA, Ustun, C, Oh, ST, Griffiths, EA, Sperr, WR, Livideanu, CB, Triggiani, M, Zanotti, R. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances 6(21):5750-5762, 2022. e-Pub 2022. PMID: 35640224.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Rozovski, U, Veletik, I, Harris, D, Li, P, Liu, Z, Jain, P, Manshouri, T, Ferrajoli, A, Burger, JA, Bose, P, Thompson, PA, Jain, N, Wierda, WG, Verstovsek, S, Keating, M, Estrov, Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clinical Lymphoma, Myeloma and Leukemia 22:S271, 2022. e-Pub 2022. PMID: 36163878.
Harrison, C, Bose, P, Mesa, RA, Gerds, A, Oh, ST, Kiladijan, JJ, Garcia-Gutierrez, V, Vannucchi, AM, Scheid, C, Sobas, M, Verstovsek, S, Buckley, S, Roman-Torres, K, Mascarenhas, J. MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia. Clinical Lymphoma, Myeloma and Leukemia 22:S326-S327, 2022. e-Pub 2022. PMID: 36163987.
Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian JJ, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S335-S336, 2022. e-Pub 2022. PMID: 36164005.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. e-Pub 2022. PMID: 36164003.
Oh S, Mesa R, Harrison C, Bose P, Gerds A, Gupta V, Swami A, Tyavanagimatt S, Buckley S, Roman-Torres K, Verstovsek S. MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S327, 2022. e-Pub 2022. PMID: 36163989.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. e-Pub 2022. PMID: 36164004.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033-1062, 2022. e-Pub 2022. PMID: 36075392.
Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Bose P, Mesa RA. Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leuk Lymphoma 63(4):1-15, 2022. e-Pub 2022. PMID: 34775887.
Vachhani P, Verstovsek S, Bose P. "Disease Modification" in Myelofibrosis: an elusive goal?. J Clin Oncol 40(11):1147-1154, 2022. e-Pub 2022. PMID: 35084934.
Gerds AT, Bose P, Hobbs GS, Kuykendall AT, Neilson LM, Song J, Klencke B, Harrison CN. Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: current evidence and real-world implications. Hemasphere 6(10):e778, 2022. e-Pub 2022. PMID: 36204692.
Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12(1):23, 2022. e-Pub 2022. PMID: 35102145.
Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol 366:83-124, 2022. e-Pub 2022. PMID: 35153007.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183-2191, 2021. e-Pub 2021. PMID: 34873347.
Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med 27(12):2192-2199, 2021. e-Pub 2021. PMID: 34873345.
Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II Study of Azacitidine with Pembrolizumab in Patients with Intermediate-1 or Higher-Risk Myelodysplastic Syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol 34(9):1673-1685, 2021. e-Pub 2021. PMID: 33990705.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Bose P, Verstovsek S. Avapritinib for Systemic Mastocytosis. Expert Rev Hematol 14(8):687-696, 2021. e-Pub 2021. PMID: 34289787.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327, 2021. e-Pub 2021. PMID: 33551345.
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome. Leuk Lymphoma 62(5):1187-1194, 2021. e-Pub 2021. PMID: 33356689.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol 144(5):484-499, 2021. e-Pub 2021. PMID: 33882481.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of Gli1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet Therapy with Venetoclax, FLT3 Inhibitor and Decitabine for FLT3-mutated Acute Myeloid Leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver N, Kadia T, Chifotides H, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Venetoclax Combinations in Patients with Acute Leukemia from Myeloproliferative Neoplasms: Single Center Experience. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol 38(5):654-664, 2020. e-Pub 2020. PMID: 32592408.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, García-Gutiérrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 4(22):5825-5835, 2020. e-Pub 2020. PMID: 33232476.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(9):1248-1269, 2020. e-Pub 2020. PMID: 32886902.
Bose P, Verstovsek S. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma 61(8):1797-1809, 2020. e-Pub 2020. PMID: 32297800.
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 29(6):525-536, 2020. e-Pub 2020. PMID: 32693648.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol 37(3):240-252, 2019. e-Pub 2019. PMID: 31013548.
Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv 3(15):2264-2271, 2019. e-Pub 2019. PMID: 31350306.
Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol 42(8):649-654, 2019. e-Pub 2019. PMID: 31305287.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2019. PMID: 30575820.
Bose P, Verstovsek S. MF Management. Hemasphere 3(suppl 2):149-152, 2019. e-Pub 2019.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2019. PMID: 30635233.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of co-treatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Bose P. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs 7(10):415-425, 2019. e-Pub 2019. PMID: 33094033.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(12):1500-1537, 2018. e-Pub 2018. PMID: 30545997.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-3, 2018. e-Pub 2018. PMID: 30242087.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis 67(10):1610-1613, 2018. e-Pub 2018. PMID: 29771293.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(9):569-575.e1, 2018. e-Pub 2018. PMID: 30122201.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res 72(9):92-95, 2018. e-Pub 2018. PMID: 30118897.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Bose P, Swaminathan M. JAK inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34(5):1-6, 2018. e-Pub 2018. PMID: 29415577.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of Ruxolitinib in combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2018. PMID: 29134664.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep 6(1):155-611, 2018. e-Pub 2018. PMID: 29375856.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2018. PMID: 28919634.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58(9):1-17, 2017. e-Pub 2017. PMID: 28140720.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal Evolution and Outcomes in Myelofibrosis After Ruxolitinib Discontinuation. Blood 130(9):1125-31, 2017. e-Pub 2017. PMID: 28674026.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is Frequently Low in Patients with Myelofibrosis: Clinical Relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma. Leuk Lymphoma 58(6):1349-1357, 2017. e-Pub 2017. PMID: 28103725.
Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel Hematological Parameters for the Evaluation of Patients with Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2017. PMID: 27494751.
Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
Bose P, Verstovsek S. Myelofibrosis: An Update on Drug Therapy in 2016. Expert Opin Pharmacother 17(18):2375-2389, 2016. e-Pub 2016. PMID: 27774820.
Bose P, Verstovsek S. Investigational histone dea¬cetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs 25(12):1393-1403, 2016. e-Pub 2016. PMID: 27756180.
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 12(11):1-12, 2016. e-Pub 2016. PMID: 27686109.
Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30(8):1803-4, 2016. e-Pub 2016. PMID: 27198052.
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 7(27):42625-42638, 2016. e-Pub 2016. PMID: 27213589.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22(5):1067-75, 2016. e-Pub 2016. PMID: 26446942.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leuk Lymphoma 57(3):1-30, 2016. e-Pub 2016. PMID: 26284612.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized Multicenter Phase 2 Study of Timed Sequential Therapy with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed Adult Acute Myeloid Leukemia (AML). Haematologica 100(9):172-179, 2015. e-Pub 2015. PMID: 26022709.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20(22):5652-62, 2014. e-Pub 2014. PMID: 25248382.
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323-36, 2014. e-Pub 2014. PMID: 24769080.
Vachhani P, Bose P. Isolated gastric myeloid sarcoma: a case report and review of the literature. Case Rep Hematol 2014:541807, 2014. e-Pub 2014. PMID: 25105036.
Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep 2(1):18-20, 2013. e-Pub 2013. PMID: 23977454.
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep 2(1):12-14, 2013. e-Pub 2013. PMID: 23977453.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 69(6):1657-67, 2012. e-Pub 2012. PMID: 22349810.
Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tfayli A. c-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res 30(11):4731-6, 2010. e-Pub 2010. PMID: 21115932.

Invited Articles

Bose P. EXABS-115-MPN Current and Emerging Therapies for Systemic Mastocytosis. Clin Lymphoma Myeloma Leuk 23(Supplement 1):S14-S17, 2023. e-Pub 2023.
Bose P. EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S65-S66, 2022. e-Pub 2022. PMID: 36164235.
Bose P. Cases in the management of polycythemia vera: a patient with progressive leukocytosis. Clin Adv Hematol Oncol 20(Suppl 16(8)):1-12, 2022. e-Pub 2022. PMID: 36125942.
Bose P. A Young Woman with Thrombocytosis. Clin Lymphoma Myeloma Leuk 20(Suppl 1):S14-S17, 2020. e-Pub 2020. PMID: 32862851.
Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol 111(2):192-199, 2020. e-Pub 2020. PMID: 31630335.
Bose P. Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk 19(suppl 1):S36-S39, 2019. e-Pub 2019.
Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol 20(1):5, 2019. e-Pub 2019. PMID: 30675650.
Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. e-Pub 2019. PMID: 31597841.
Bose P, Verstovsek S. Accelerated Phase Myelofibrosis. Clin Lymphoma Myeloma Leuk 18(Suppl. 1):S40-S42, 2018. e-Pub 2018.
Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep 13(3):164-172, 2018. e-Pub 2018. PMID: 29796726.
Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18(1):1-12, 2018. e-Pub 2018. PMID: 29277359.
Bose P. Myelofibrosis with cytopenias. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S30-S31, 2017. e-Pub 2017.
Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 17S:S43-S52, 2017. e-Pub 2017. PMID: 28760302.
Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 18(3):17, 2017. e-Pub 2017. PMID: 28286924.
Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. e-Pub 2016. PMID: 27521306.
Bose P, Grant S. Rational combinations of targeted agents in AML. J Clin Med 4(4):634-664, 2015. e-Pub 2015. PMID: 26113989.
Bose P, Qubaiah O. A review of tumor lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36(3):299-326, 2011. e-Pub 2011. PMID: 21501203.

Editorials

Bose, P, Vachhani, P. Ruxolitinib for myelofibrosis. Cancer 130(24):4224-4226, 2024. PMID: 39396121.
Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma 60(7):1603-1605, 2019. PMID: 30724681.
Bose P, Konopleva MY. ORY-1001: Overcoming the differentiation block in AML. Cancer Cell 33(3):342-343, 2018. PMID: 29533778.
Bose P, Konopleva MY. T-PLL: another check on the venetoclax list?. Blood 130(23):2447-2448, 2017. PMID: 29217697.
Bose P, Verstovsek S. Ruxolitinib for Essential Thrombocythemia?. Oncoscience 4(11-12):148-149, 2017. PMID: 29344542.
Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res 38(8):862-5, 2014. PMID: 24996975.
Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget 3(12):1499-500, 2012. PMID: 23439314.
Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. Expert Rev Hematol 5(5):475-8, 2012. PMID: 23146050.

Abstracts

Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. e-Pub 2022. PMID: 36163821.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Mesa R, Palmer J, Bose P, Oh S, Rampal R, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Symptom Burden in Patients with Myelofibrosis who Have Moderate or Severe Thrombocytopenia: a Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study. J Natl Compr Canc Netw 20(3.5), 2022. e-Pub 2022.
DeAngelo DJ, Reiter A, Radia D, Deininger MW, George TI, Panse J, Vannucchi AM, Jentzsch M, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh S, Sen J, Lin H, Mar BG, Gotlib J. PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). Clin Cancer Res, 2021. e-Pub 2021.
Maiti A, DiNardo CD, Wang SA, Jorgensen JL, Kadia TM, Daver N, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour E, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano K, Pierce SA, Kantarjian HM, Konopleva M, Ravandi AF. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Chien KS, Borthakur G, Naqvi K, Daver N, Bravo GM, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Sheppard K, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero AG. Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome. Blood 136, 2020. e-Pub 2020.
Morita K, Kantarjian HM, Bravo GM, Sasaki K, Daver N, Jabbour E, Alvarado Y, Chien KS, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva M, Rausch CR, Gasior Y, Garcia-Manero AG. A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 136, 2020. e-Pub 2020.
Rivera D, Verstovsek S, Bose P, Pemmaraju N, Zhou L, Pierce SA, Kantarjian HM, Estrov ZE, Masarova AL. Outcomes of Patients with Myelofibrosis and Favorable Karyotype. Blood 136, 2020. e-Pub 2020.
Chien KS, Borthakur G, Naqvi K, Daver N, Bravo GM, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Sheppard K, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero AG. Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood 136, 2020. e-Pub 2020.
Fiskus W, Mill CP, Birdwell C, Lara BH, Bose P, Masarova L, Kadia TM, Khoury JD, Manshouri T, Verstovsek S, N Bhalla AK. Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells. Blood 136, 2020. e-Pub 2020.
Venugopal S, Verstovsek S, Bose P, Pemmaraju N, Zhou L, Pierce SA, Kantarjian HM, Estrov ZE, Masarova AL. Diploid Karyotype Represents a Favorable Prognostic Subgroup in Blast Phase Myeloproliferative Neoplasms. Blood 136, 2020. e-Pub 2020.
Morita K, Bravo GM, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Kantarjian HM, Garcia-Manero AG. Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 136, 2020. e-Pub 2020.
Talpaz M, Rampal RK, Verstovsek S, Harrison C, Drummond MW, Kiladjian J, Vannucchi A, Kremyanskaya M, Schiller GJ, Patriarca A, Gorkom GV, Bose P, Hoffman R, Luptakova K, Christo J, Wang J, Mertz JA, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Mascarenhas AJ. CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study. Blood 136, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Masarova L, Kadia TM, Paul S, Nichols D, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Bose P, Khouri R, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour AE. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Bravo GM, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Short NJ, Issa GC, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravandi AF. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Blood 136, 2020. e-Pub 2020.
Reville PK, Kantarjian HM, Borthakur G, Yilmaz M, Montalban-Bravo G, DiNardo CD, Andreeff M, MD, Daver N, Jain N, Kornblau SM, Jabbour E, Short NJ, Alvarado Y, Ohanian M, Bose P, Masarova L, Wang SA, S Tidwell RS, Estrov ZE, Garcia-Manero G, Konopleva M, Ravandi F, M Kadia AT. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 136, 2020. e-Pub 2020.
Verstovsek S, Mascarenhas J, Kremyanskaya M, Hoffman R, Rampal RK, Gupta V, Talpaz M, Granacher N, Leber B, Kiladjian J, Vannucchi A, Bose P, McMullin MF, Sirhan S, Ribrag V, Luptakova K, Christo J, Wang J, Mertz JA, Colak G, Shao J, Bobba S, Trojer P, Senderowicz A, Harrison AC. CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Maiti A, Konoplev S, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, Konopleva AM. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Blood 136, 2020. e-Pub 2020.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, G Wierda AW. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood 136, 2020. e-Pub 2020.
Maiti A, DiNardo CD, Ravandi F, Pemmaraju N, Borthakur G, Bose P, Issa GC, Kadia TM, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano KS, Pierce SA, Kantarjian HM, Daver N, Konopleva AM. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Blood 136, 2020. e-Pub 2020.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov ZE, Kantarjian HM, Verstovsek S. Improved Survival of Patients with Myelofibrosis in the Last Decade. Blood 136, 2020. e-Pub 2020.
Thompson PA, Ferrajoli A, Jain N, Wang Y, Peterson CB, Garg N, Wei C, Ayala A, Kadia TM, Bose P, Pemmaraju N, Short NJ, Keating MJ, G Wierda AW. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood 136, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala SE, Yilmaz M, Ferrajoli A, Bose P, Thompson PA, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger JA, Borthakur G, Pemmaraju N, Shilpa Paul RK, Pierce SA, Cortes JE, M Kantarjian AH. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood 136, 2020. e-Pub 2020.
Gotlib J, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny H, Tugnait M, Schmidt-Kittler O, Evans EK, Lin H, Mar BG, Deininger MW, J DeAngelo AD. Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. Blood 136, 2020. e-Pub 2020.
Short NJ, Kadia TM, DiNardo CD, Pemmaraju N, Borthakur G, Garcia-Manero G, Jabbour E, Sasaki K, Issa GC, Montalban-Bravo G, Bose P, Burger JA, Miller D, Alexander-Williams L, Ravandi F, Konopleva M, Kantarjian HM, Daver AN. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood 136, 2020. e-Pub 2020.
Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver N, Jabbour E, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Nguyen-Cao M, Richie MA, Dobbins MH, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek AS. Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood 136, 2020. e-Pub 2020.
Rausch CR, DiPippo A, Bose P, Kontoyiannis DP. Breakthrough Invasive Fungal Infections (bIFI) Are Uncommon in Patients with Newly Diagnosed Acute Leukemia Receiving Primary Antifungal Prophylaxis. Blood 136, 2020. e-Pub 2020.
Kim K, Maiti A, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Alvarado Y, Ferrajoli A, Jabbour E, Jain N, Ohanian M, Takahashi K, Thompson PA, Rausch CR, Montalbano K, Pierce SA, Patel KP, Garcia-Manero G, Kantarjian HM, DiNardo CD, Konopleva AM. Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine. Blood 136, 2020. e-Pub 2020.
Lachowiez CA, Borthakur G, Loghavi S, Zeng Z, Kadia TM, Masarova L, Takahashi K, Tippett GD, Naqvi K, Bose P, Jabbour E, Ravandi F, Daver NG, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian HM, Konopleva M, Dinardo CD, Halpern AB. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. J Clin Oncol 38 (suppl), 2020. e-Pub 2020.
Kadia TM, Garcia-Manero G, Yilmaz M, Dinardo CD, Konopleva M, Montalban-Bravo G, Borthakur G, Jabbour E, Jain N, Andreeff M, Short NJ, Issa GC, Ohanian M, Bose P, Daver NG, Wang SA, Tidwell R, Estrov Z, Ravandi F, Kantarjian HM. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 38 (suppl), 2020. e-Pub 2020.
Maiti A, MBBS, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian M, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz ME, MD, Jain N, MD, Kornblau SM, MD, Bravo GM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD, DiNardo CD, MD, MSc. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134:738, 2019. e-Pub 2019.
Jain N, MD, Keating MJ, MBBS, Thompson PA, MBBS, Ferrajoli A, MD, Burger JA, MD, PhD, Borthakur GM, MD, Takahashi K, MD, Estrov ZE, MD, Fowler NH, MD, Kadia TM, MD, Konopleva MY, MD, PhD, Alvarado Y, MD, Yilmaz M, MD, DiNardo CD, MD, MSc, Bose P, MD, Ohanian M, DO, Pemmaraju N, MD, Jabbour E, Sasaki K, MD, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Garg N, MD, Wang X, MS, Sondermann K, BA, Cruz N, RN, Wei C, PhD, Ayala A, RN, Plunkett W, PhD, Kantarjian HM, MD, Gandhi V, PhD, Wierda WG, MD, PhD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134:34, 2019. e-Pub 2019.
Rozovski U, MD, Harris DM, PhD, Li P, PhD, Liu Z, BS, Manshouri T, PhD, Veletic I, MD, Jain P, MBBS, MD, DM, PhD, Ferrajoli A, MD, Burger JA, MD, PhD, Bose P, MD, Thompson PA, MBBS, Jain N, MD, Verstovsek S, MD, PhD, Wierda WG, MD, PhD, Keating MJ, MBBS, Estrov ZE, MD. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood 134:3018, 2019. e-Pub 2019.
Rampal RK, MD, PhD, Verstovsek S, MD, PhD, Devlin SM, PhD, King AC, PharmD, BCOP, Stein EM, MD, Pemmaraju N, MD, Mauro MJ, MD, Kadia TM, MD, Montalban-Bravo G, MD, Alvarez K, RN, Ard N, Goodman T, Taylor B, Bose P, MD. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood 134:4163, 2019. e-Pub 2019.
Thompson PA, MBBS, Keating MJ, MBBS, Jain N, MD, Ferrajoli A, MD, Kadia TM, MD, Bose P, MD, Wierda WG, MD, PhD. Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. Blood 134:358, 2019. e-Pub 2019.
Jain N, MD, Thompson PA, MBBS, Burger JA, MD, PhD, Ferrajoli A, MD, Takahashi K, MD, Estrov ZE, MD, Borthakur GM, MD, Bose P, MD, Kadia TM, MD, Pemmaraju N, MD, Sasaki K, MD, Garg N, MD, Wang X, MS, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Lopez W, RN, Ayala A, RN, Plunkett W, PhD, Gandhi V, PhD, Kantarjian HM, MD, O'Brien S, MD, Keating MJ, MBBS, Wierda WG, MD, PhD. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134:357, 2019. e-Pub 2019.
Rozovski U, MD, Harris DM, PhD, Li P, PhD, Liu Z, BS, Manshouri T, PhD, Veletic I, MD, Jain P, MBBS, MD, DM, PhD, Ferrajoli A, MD, Burger JA, MD, PhD, Bose P, MD, Thompson PA, MBBS, Jain N, MD, Verstovsek S, MD, PhD, Wierda WG, MD, PhD, Keating MJ, MBBS, Estrov ZE, MD. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood 134:3024, 2019. e-Pub 2019.
Guerra VA, MD, Kantarjian HM, MD, Cortes JE, MD, Garcia-Manero G, MD, Masarova L, MD, Pemmaraju N, MD, Jabbour E, Kadia TM, MD, DiNardo CD, MD, MSc, Zhou L, Pierce SA, BSN, BA, Borthakur GM, MD, Wierda WG, MD, PhD, Ferrajoli A, MD, Sasaki K, MD, Takahashi K, MD, Naqvi K, MD, MPH, Alvarado Y, MD, Ohanian MN, DO, Jain N, MD, Bose P, MD, Ravandi F, MD, Konopleva MY, MD, PhD, Estrov ZE, MD, Verstovsek S, MD, PhD, Daver NG, MD. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 134:4237, 2019. e-Pub 2019.
Masarova L, MD, Verstovsek S, MD, PhD, Bose P, MD, Pemmaraju N, MD, Cortes JE, MD, Jabbour E, MD, Ohanian M, DO, Zhou L, Pierce SA, BSN, BA, Gergis R, Borthakur GM, MD, Kadia TM, MD, DiNardo CD, MD, MSc, Ravandi F, MD, Konopleva MY, MD, PhD, Naqvi K, MD, MPH, Sasaki K, MD, Estrov ZE, MD, Garcia-Manero G, MD, Bueso-Ramos CE, MD, PhD, Kantarjian HM, MD, Daver NG, MD. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134:1656, 2019. e-Pub 2019.
Mascarenhas J, MD, Kremyanskaya M, Hoffman R, MD, Bose P, MD, Talpaz M, MD, Harrison CN, Professor, Gupta V, MD, FRCP, FRCPath, Leber B, MD, Sirhan S, MD, Kabir S, MD, Senderowicz A, MD, Shao J, MS, Mertz J, PhD, Trojer P, PhD, Verstovsek S, MD, PhD. MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood 134:670, 2019. e-Pub 2019.
Fiskus W, BSc, PhD, Mill CP, PhD, BA, Karkhanis V, PhD, Lara BH, Bose P, MD, Masarova L, MD, Kadia TM, MD, Shao N, Bhalla I, Maher JV, Khoury JD, MD, Sharma S, MD, Manshouri T, PhD, Verstovsek S, MD, PhD, Bhalla KN, MD. Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells. Blood 134:1274, 2019. e-Pub 2019.
Pemmaraju N, MD, Carter BZ, PhD, Kantarjian HM, MD, Cortes JE, MD, Bose P, MD, Kadia TM, MD, Garcia-Manero G, MD, Bueso-Ramos CE, MD, PhD, DiNardo CD, MD, MSc, Bledsoe S, Daver NG, MD, Popat U, MD, Konopleva MY, MD, PhD, Ohanian M, DO, Pierce SA, BSN, BA, Zhou L, Estrov ZE, MD, Borthakur GM, MD, Mak PY, Jain N, MD, Jabbour E, Verstovsek S, MD, PhD. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 134:555, 2019. e-Pub 2019.
Maiti A, MBBS, DiNardo CD, MD, MSc, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian MN, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz ME, MD, Jain N, MD, Kornblau SM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, MD, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134:2637, 2019. e-Pub 2019.
Kantarjian HM, MD, Richard-Carpentier G, MD, Borthakur GM, MD, Ravandi F, MD, Naqvi K, MD, MPH, Sasaki K, MD, Kadia TM, MD, Verstovsek S, MD, PhD, Garcia-Manero G, MD, DiNardo CD, MD, MSc, Pemmaraju N, MD, Daver NG, MD, Bose P, MD, Pierce SA, BSN, BA, Dara S, MBBS, Jabbour E, Shoukier M, Cortes JE, MD. Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood 134:2941, 2019. e-Pub 2019.
Jain N, MD, Keating MJ, MBBS, Thompson PA, MBBS, Burger JA, MD, PhD, Ferrajoli A, MD, Estrov ZE, MD, Borthakur GM, MD, Takahashi K, MD, Bose P, MD, Fowler NH, MD, Kadia TM, MD, Daver NG, MD, Konopleva MY, MD, PhD, Alvarado Y, MD, Yilmaz M, MD, DiNardo CD, MD, MSc, Ohanian M, DO, Pemmaraju N, MD, Jabbour E, Sasaki K, MD, Kanagal-Shamanna R, MD, Patel K, MD, PhD, Jorgensen JL, MD, PhD, Wang SA, MD, Garg N, MD, Wang X, MS, Sondermann K, BA, Cruz N, RN, Wei C, PhD, Ayala A, RN, Plunkett W, PhD, Kantarjian HM, MD, Gandhi V, PhD, Wierda WG, MD, PhD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 134:359, 2019. e-Pub 2019.
Maiti A, MBBS, Rausch CR, PharmD, Cortes JE, MD, Pemmaraju N, MD, Daver NG, MD, Ravandi F, MD, Garcia-Manero G, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Ohanian M, DO, Short NJ, MD, Alvarado Y, MD, Benton CB, MD, Kadia TM, MD, Takahashi K, MD, Yilmaz M, MD, Jain N, MD, Kornblau SM, MD, Sasaki K, MD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Issa GC, MD, Jabbour E, MD, Masarova L, MD, Rytting ME, MD, Thompson PA, MBBS, Wang SA, MD, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, RN, Zhang Q, PhD, Cavazos A, Ma H, MS, Bivins CA, RN, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, RN, Pierce SA, BSN, BA, Ning J, PhD, Qiao W, PhD, Welch JS, MD, PhD, Patel KP, MBBS, PhD, Kantarjian HM, MD, Konopleva MY, MD, PhD, DiNardo CD, MD, MSc. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134:645, 2019. e-Pub 2019.
Samra B, MD, Richard-Carpentier G, MD, Ravandi F, MD, Kadia TM, MD, Guerra VA, MD, Daver NG, MD, DiNardo CD, MD, MSc, Issa GC, MD, Bose P, MD, Yilmaz M, MD, Ohanian M, DO, Borthakur GM, MD, Garcia-Manero G, MD, Pierce SA, BSN, BA, Cortes JE, MD, Kantarjian HM, MD, Short NJ. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood 134:3834, 2019. e-Pub 2019.
Taylor F, Shields A, Li S, Yip C, Padilla B, Green T, Radia D, Deininger M, Gotlib JR, Bose P, Drummond MW, Hexner E, Robinson W, Quiery, Jr A, Winton EF, DeAngelo DJ, Mar B. PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS, 2019. e-Pub 2019.
Yilmaz M, MD, Kantarjian HM, MD, Wang X, MS, Khoury JD, MD, Ravandi F, MD, Jorgensen JL, MD, PhD, Short NJ, MD, Loghavi S, MD, Cortes JE, MD, Garcia-Manero G, MD, Kadia TM, MD, Sasaki K, MD, Konopleva MY, MD, PhD, Takahashi K, MD, Wierda WG, MD, PhD, Jain N, MD, Verstovsek S, MD, PhD, Estrov ZE, MD, Bose P, MD, Pierce SA, BSN, BA, Garris R, MSc, O'Brien SM, MD, Jabbour E, MD. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134:1297, 2019. e-Pub 2019.
Chien KS, MD, Borthakur GM, MD, Naqvi K, MD, MPH, Daver NG, MD, Cortes JE, MD, DiNardo CD, MD, MSc, Jabbour E, MD, Andreeff M, MD, PhD, Alvarado Y, MD, Bose P, MD, Jain N, MD, Sheppard K, BSN, RN, Klingner-Winton C, Pierce SA, BSN, BA, Dong XQ, Soltysiak K, PhD, Kantarjian HM, MD, Garcia-Manero G, MD. Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood 134:4240, 2019. e-Pub 2019.
Lee LW, Ching T, Patel K, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Burger J, Keating M, Bose P, Wierda WG, Kirsch I. Assessment of immunoglobulin heavy chain variable region (IGHV) mutation status with a next-generation sequencing (NGS) immunosequencing assay for minimal residual disease (MRD), 2019. e-Pub 2019.
Jain N, Thompson PA, Burger JA, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Jorgensen J, Wang S, Plunkett W, Gandhi V, Kantarjian H, O’Brien S, Keating M, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-line Treatment of patients with CLL with Mutated IGHV and without TP53 Aberrations, 2019. e-Pub 2019.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132, 2018. e-Pub 2018.
Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju N, Kadia TM, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood 132, 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Kadia TM, Garcia-Manero G, Patel K, Loghavi S, Sasaki K, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Kadia TM, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour EJ, Verstovsek S. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, Alvarado Y, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi R, Sun B, Mill CP, Nowak AJ, Kornblau SM, Bose P, Kadia TM, DiNardo CD, Masarova L, Horrigan S, Khoury JD, Sharma S, Verstovsek S, Bhalla KN. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood 132, 2018. e-Pub 2018.
Kadia TM, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Bhalla KN, Pemmaraju N, Jain N, Malla R, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood 132, 2018. e-Pub 2018.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 132, 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, Konopleva MY, Garcia-Manero G, Takahashi K, DiNardo CD, Bose P, Andreeff M, Ravandi F, Cortes JE. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
Tallis E, Kantarjian HM, Major CK, Vazquez M, Borthakur G, Bose P, Ravandi F, Garcia-Manero G, Kadia TM, Wierda WG, Ferrajoli A, Pemmaraju N, Daver NG, DiNardo CD, Konopleva MY, Kornblau SM, Champlin RE, Jabbour EJ, Pierce SA, Cortes JE. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood 132, 2018. e-Pub 2018.
Alfayez M, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Cortes JE, Kadia TM. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 132, 2018. e-Pub 2018.
Rozovski U, Li P, Harris DM, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov ZE. Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage. Blood 132, 2018. e-Pub 2018.
Masarova L, Bose P, Pemmaraju N, Estrov ZE, Zhou L, Pierce SA, Cortes JE, Kantarjian HM, Verstovsek S. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018. e-Pub 2018.
Rausch CR, Paul S, Bravo GM, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132, 2018. e-Pub 2018.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov ZE. CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB. Blood 132, 2018. e-Pub 2018.
Rampal RK, Verstovsek S, Devlin SM, Stein EM, Kadia TM, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood 132, 2018. e-Pub 2018.
Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132, 2018. e-Pub 2018.
Garcia-Manero G, Jabbour EJ, Konopleva MY, Daver NG, Borthakur G, DiNardo CD, Bose P, Patel P, Komrokji RS, Shastri A, Roboz GJ, Miller RM, Arbe-Barnes S, Reilly M, McGuirk P, Kearney T, Keogh B, Kantarjian HM. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood 132, 2018. e-Pub 2018.
Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, Estrov ZE, Kadia TM, Takahashi K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 132, 2018. e-Pub 2018.
Richard-Carpentier G, Kantarjian HM, Ravandi F, Kadia TM, Borthakur G, Garcia-Manero G, DiNardo CD, Wierda WG, Daver NG, Pemmaraju N, Bose P, Konopleva MY, Andreeff M, Verstovsek S, Krause HM, Aung FM, Cortes JE. Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood 132, 2018. e-Pub 2018.
Alfayez M, Kantarjian HM, Short NJ, Assi R, Khouri M, Ravandi F, Paul S, Rausch CR, Nasnas P, Borthakur G, DiNardo CD, Kadia TM, Daver NG, Garcia-Manero G, Naqvi K, Bose P, O'Brien SM, Cortes JE, Jabbour EJ. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood 132, 2018. e-Pub 2018.
Masarova L, Verstovsek S, Cortes JE, Pemmaraju N, Bose P, Ohanian MN, Zhou L, Pierce SA, Gergis R, Borthakur G, Estrov ZE, Garcia-Manero G, Kantarjian HM, Daver NG. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132, 2018. e-Pub 2018.
Gotlib JR, Radia D, DeAngelo DJ, Bose P, Drummond MW, Hexner EO, Robinson WA, Conlan MG, Oren RG, Shi H, Deininger MW. Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood 132, 2018. e-Pub 2018.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib. Blood 130, 2017. e-Pub 2017.
Bose P, Pemmaraju N, Schroeder K, Ferrajoli A, Jabbour EJ, Daver N, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood 130, 2017. e-Pub 2017.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells. Blood 130, 2017. e-Pub 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. Blood 130, 2017. e-Pub 2017.
Bose P, Chen L, Cruz N, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll M, Jain N, Wierda WG, Keating MJ, Gandhi V. A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL). Blood 130, 2017. e-Pub 2017.
Falchi L, Chihara D, Bose P, Estrov Z, Kantarjian HM, Ravandi F, Verstovsek S. Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes. Blood 130, 2017. e-Pub 2017.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 130, 2017. e-Pub 2017.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, KC D, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M, Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 130, 2017. e-Pub 2017.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes J, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, 2017. e-Pub 2017.
Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, Huynh-Lu J, Nguyen-Cao M, Wang X, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood 130, 2017. e-Pub 2017.
Yilmaz M, Kantarjian HM, Wang X, KC D, Khoury JD, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda W, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130, 2017. e-Pub 2017.
Naqvi K, Cortes JE, Skinner J, Jabbour EJ, Pemmaraju N, Bose P, Thompson PA, Borthakur G, Estrov Z, Kantarjian HM. Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Blood 130, 2017. e-Pub 2017.
Hu B, Patel K, Wang X, H-C C, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood 130, 2017. e-Pub 2017.
Boddu P, Mansurov A, Masarova L, Bose P, Patel KP, Estrov Z, Kantarjian HM, Verstovsek S. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood 130, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 130, 2017. e-Pub 2017.
Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. Blood 130, 2017. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Takahashi K, Garg N, Wang X, Gandhi V, Plunkett W, Kanagal-Shamanna R, Patel K, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 130, 2017. e-Pub 2017.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2017. e-Pub 2017.
Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 130, 2017. e-Pub 2017.
Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda W. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood, 2017. e-Pub 2017.
Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 130, 2017. e-Pub 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130, 2017. e-Pub 2017.
Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130, 2017. e-Pub 2017.
Garcia-Manero G, Daver N, Montalban-Bravo G, Jabbour E, DiNardo C, Kornblau S, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes J, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez G, Bueso-Ramos C, Gasior Y, Bayer V, Pierce S, Yang H, Colla S, Kantarjian H. AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS). Haematologica (Roma) 102:183, 2017. e-Pub 2017.
Naqvi K, Cortes JE, Skinner JA, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson PA, Kantarjian HM. Early Results of Lower Dose Dasatinib, 50mg Daily, in Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase. J Clin Oncol 35. e-Pub 2017.
Naqvi K, Kadia T, Borthakur G, Takahashi K, Bose P, Daver N, Alvarado Y, Ohanian M, DiNardo C, Jabbour E, Garcia-Manero G, Kantarjian H, Patel A, Ravandi F. PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR. Haematologica (Roma) 102:375, 2017. e-Pub 2017.
Bose P, Nazha A, Komrokji R, Savona M, Patel K, Pierce S, Al Ali N, Sochacki A, Shaver A, Daver N, DiNardo C, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Sekeres M, Maciejewski J, Verstovsek S. MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM -. Haematologica (Roma) 102:118, 2017. e-Pub 2017.
Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes JE, Kantarjian HM, Verstovsek S. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. J Clin Oncol 35, 2017. e-Pub 2017.
Masarova L, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. J Clin Oncol 35. e-Pub 2017.
Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G. Updated results from Phase 2 Study of Guadecitabine for Patients with Higher Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia. J Clin Oncol 35. e-Pub 2017.
Assi R, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Kadia TM, DiNardo CD, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). J Clin Oncol 35. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Gandhi V, Plunkett W, Lopez W, Kantarjian HM, O’Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV and Non-del(17p). J Clin Oncol 35. e-Pub 2017.
Boddu P, Jorgensen JL, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour E, Garcia-Manero G, Cortes JE, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces risk of relapse. J Clin Oncol 35. e-Pub 2017.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128, 2016. e-Pub 2016.
Pemmaraju N, Carter BZ, Kantarjian H, Cortes J, Kadia T, Garcia-Manero G, DiNardo C, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle C, Salinas K, Mak PY, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128, 2016. e-Pub 2016.
Sasaki K, Jabbour E, O'Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Acute Lymphoblastic Leukemia (ALL) by Age Group over 35 Years: A Single Institution Experience. Blood 128, 2016. e-Pub 2016.
Masarova L, Popat U, Bose P Champlin R, Cortes J, Kantarjian H, Verstovsek S. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. Blood 128, 2016. e-Pub 2016.
Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa G, Daver N, Jabbour E, DiNardo C, Bueso-Ramos C, Patel K, Kornblau S, Konopleva M, Borthakur G, Kadia T, Cortes J, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian H. Archetypes of AML defined using whole exome sequencing and clinical characteristics in a diverse group of patients. Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128, 2016. e-Pub 2016.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells. Blood 128, 2016. e-Pub 2016.
Bose P, Daver N, Jabbour EJ, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek S. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) as Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128, 2016. e-Pub 2016.
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes J, DiNardo C, Jabbour E, Kadia T, Kornblau S, Ohanian M, Alfonso A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Initial results of a Phase 2 Study of Guadecitabine (SGI-110), A Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128, 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin C, Khouri MR, Cortes JE, Garris R, O'Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood 128, 2016. e-Pub 2016.
Jain P, Wang S, Kantarjian H, Sarwari N, Patel KP, Bose P, Pierce S, Kadia TM, Daver N, Pemmaraju N, Cortes J, Verstovsek S. Aleukemic mast cell leukemia (aMCL) – clinical characteristics and outcomes. Blood 128, 2016. e-Pub 2016.
Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 128, 2016. e-Pub 2016.
Khan M, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo C, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine as Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri RB, Alvarado Y, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Garris R, Schroeder H, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O'Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128, 2016. e-Pub 2016.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Cytogenetic risk stratification in primary versus post-essential thrombocythemia / post-polycythemia vera myelofibrosis. Blood 128. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda WG, Keating M, Estrov Z. Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo. Blood 128, 2016. e-Pub 2016.
Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128, 2016. e-Pub 2016.
Abaza Y, Kantarjian H, Jabbour E, Thomas D, Kadia T, Borthakur G, Burger J, Wierda W, Jain N, Faderl S, O'Brien S, Konopleva M, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose P, Thompson P, Kelly M, Garris R, Garcia-Manero G, Cortes J, Ravandi F. Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated Adult T-cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128, 2016. e-Pub 2016.
Ohanian M, Kantarjian H, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt J, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-dose Ara-C in Multiply Relapsed/ Refractory FLT3+ AML. Blood 128, 2016. e-Pub 2016.
Strati P, Bose P, Gaw K, Zhou L, Pierce S, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S. Immature Platelet Fraction Is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. Blood 128, 2016. e-Pub 2016.
Masarova L, MD, Bose P, MD, pemmaraju N, MD, Newberry KJ, PhD, Bueso-Ramos CE, PhD MD, Cortes JE, MD, Kantarjian HM, MD, Verstovsek S, MD, PhD. Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis. Blood 128(22):4265, 2016. e-Pub 2016.
Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, MKadia T, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DDiNardo C, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22):3975, 2016. e-Pub 2016.
Alhuraiji A, Masarova L, Bose P, Daver NG, Cortes JE, Pierce S, Kantarjian HM, Verstovsek S. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. J Clin Oncol 34, 2016. e-Pub 2016.
Masarova L, Bose P, Pemmaraju N, Daver NG, Newberry K, Cortes JE, Kantarjian HM, Verstovsek S. Does therapy-related myelofibrosis exist? Analysis of 1100 myelofibrosis cases from a single institution. J Clin Oncol 34, 2016. e-Pub 2016.
Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes JE, Kantarjian HM, Verstovsek S. Do Patients with Post-Essential Thrombocythemia and post-Polycthemia Vera Differ from Patients with Primary Myelofibrosis?. Blood 126(23), 2015. e-Pub 2015.
KC B, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23), 2015. e-Pub 2015.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
Yilmaz M, Kantarjian HM, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Takahashi K, Wierda WG, Jain N, Verstovsek S, Estrov Z, Bose P Pierce S, Jabbour E. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood 126(23), 2015. e-Pub 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Bravo Montalban G, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23), 2015. e-Pub 2015.
Holkova B, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Singh AG, Dean A, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 124(21), 2014. e-Pub 2014.
Zeidner JF, Foster MC, Blackford A, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy Y, Tibes R, Gojo I, Gocke CD, Greer JM, Cain JM, Little RF, Wright JJ, Doyle L, Smith B, Karp JE. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 32, 2014. e-Pub 2014.
Holkova B, Kmieciak M, Bose P, Barr PM, Tombes MB, Shrader E, Cebula E, Pierce E, Herr MM, Sankala H, Feng C, Fisher RI, Grant S, Friedberg JW. Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood 122, 2013. e-Pub 2013.
Holkova B, Perkins E, Bose P, Sullivan D, Baz RC, Tombes MB, Shrader E, Ramakrishnan V, Wan W, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms – Update of the “Bolus” Infusion Schedule of Alvocidib. Blood 120(21), 2012. e-Pub 2012.
Holkova B, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis – One Year Update. Blood 120(21), 2012. e-Pub 2012.
Li J, Gatesman ML, Newland AM, Sabo R, Bose P. FLAG ± Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience. Blood 120(21), 2012. e-Pub 2012.
Zeidner JF, Gerber JM, Blackford A, Litzow M, Foster M, Morris L, Gojo I, Lancet J, Bose P, Tibes R, Strickland S, Greer J, Drye M, Meads K, Doyle L, Little RF, Wright JJ, Karp JE. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012. e-Pub 2012.
Holkova B, Shea TC, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 120(21), 2012. e-Pub 2012.
Bose P, Holter JL, Selby GB. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Blood 112(11):1338, 2008. e-Pub 2008.

Book Chapters

Bose, P, Verstovsek, S. JAK Inhibitors for the Management of Myeloproliferative Neoplasms, 567-576, 2023.
Pasca, S, Chifotides, H, Verstovsek, S, Bose, P. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN, 83-124, 2022.
Bose P, Masarova L, Amin H, Verstovsek S. Philadelphia Chromosome Negative Myeloproliferative Neoplasms. In: MD Anderson Manual of Medical Oncology. 4. McGraw Hill, 2022.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice, 2020.
Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice. BMJ Publishing Group Limited, 2018.
Bose P, Verstovsek S. Polycythemia vera. In: BMJ Best Practice, 2016.
Dai Y, Bose P, Grant S. Cell cycle regulation and hematologic disorders. In: Williams Hematology. 9. Mc-Graw Hill, 2015.
Bose P, Grant S. Bcl-2 family: translational aspects. In: Targeted Therapy of Acute Myeloid Leukemia. Springer, 67-94, 2015.
Batalo MS, Bose P, Holkova B, Grant S. Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition. In: Resistance to Proteasome Inhibitors in Cancer. Springer, 149-179, 2014.
Bose P, Vachhani P. Can we cure CML without transplantation?. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova, 279-326, 2014.
Ustun C, Warlick E, Bose P, Radich JP, Goldman JM. Summary of treatment and recommended follow-up of CML patients. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova, 183-190, 2014.
Park H, Poklepovic A, Bose P. Emerging therapeutic options for metastatic exocrine pancreatic cancer. In: Pancreas: Anatomy, Diseases and Health Implications. Nova, 159-172, 2012.
Poklepovic A, Bose P. Molecularly Targeted Therapy: Imatinib and Beyond. In: Gastrointestinal Stromal Tumor. InTech, 47-60, 2012.
Bose P, Verstovsek S. Polycythemia vera. In: Cancer Consult: Uncertainties and Controversies in the Diagnosis & Management of Cancer. 2nd. Wiley-Blackwell Health Sciences, John Wiley and Sons.

Letters to the Editor

Koschmieder, S, Bose, P, Ellis, M, Gupta, V, Kiladjian, JJ, Mascarenhas, J, Mathews, V, Passamonti, F, Harrison, C. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias. Leukemia 38: 1831-1838, 2024.
Bose P, Holter JL, Selby GB. More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia (author reply). N Engl J Med 361: 931-932, 2009.

Less

Selected Presentations & Talks

Local Presentations

2024. JAK inhibition for myelofibrosis: past, present and future. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2024. JAK Inhibition for the Treatment of Myelofibrosis. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2024. Myelofibrosis Therapy Updates from ASH 2023. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2023. MPN Therapy Updates from ASCO/EHA 2023. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2023. Novel Therapeutic Strategies for Myelofibrosis: Current and Future Directions. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2023. Update on Systemic Mastocytosis. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2023. JAKi-based Frontline Combinations in Myelofibrosis: Focus on Selinexor. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2022. Current Treatment Practices and Unmet Needs in Myelofibrosis. Conference. Curio Science. Houston, TX, US.
2022. Disease Modification in Myelofibrosis: are we there yet?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Systemic Mastocytosis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. Myelofibrosis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Update on Sytemic Mastocytosis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Pelabresib (CPI-0610) in myelofibrosis: MANIFEST data. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2020. Drug Development for Myelofibrosis: State of the Art. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2020. A pilot study of the SLAMF7 monoclonal antibody, elotuzumab, in myelofibrosis. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2019. Systemic Mastocytosis. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2018. Atypical MPN. Conference. UT MDACC. Houston, TX, US.
2018. Myelofibrosis. Conference. Baylor College of Medicine. Houston, TX, US.
2017. Myelofibrosis with cytopenias. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Building on JAK inhibition and other novel targets for drug development in myelofibrosis. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Does anything work for post-MPN AML?. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2017. Lower Dose Ibrutinib for Chronic Lymphocytic Leukemia. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2016. Rational Combinations and other Translational Projects in Leukemia. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
2014. Rational Combinations of Targeted Agents in AML. Conference. UT MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2024. Personalizing Myelofibrosis Care: Expert Insights on New Evidence and Novel Strategies (CME accredited). Conference. Alaska Oncology and Hematology, LLC. Anchorage (virtual speaker), AK, US.
2023. A Community Practitioner’s Guide to Contemporary Management of Polycythemia Vera: Data Review and Case Challenges Illustrating Current Best Practice. Conference. Jackson Oncology Associates. Jackson (Virtual Speaker), MS, US.
2023. CASES in Myelofibrosis. Conference. Aptitude Health. Virtual, US.
2023. CASES in Myelofibrosis. Conference. Aptitude Health. Virtual, US.
2023. Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis (CME-accredited). Conference. Lankenau Hospital. Wynnewood (Virtual Speaker), PA, US.
2023. A Community Practitioner’s Guide to Contemporary Myelofibrosis Care: Data Review and Case Challenges Illustrating Current Therapeutic Standards (CME-accredited). Conference. California Pharmacists Association. Fremont (Virtual Speaker), CA, US.
2022. Opinions in Myelofibrosis. Conference. Curio Science. Virtual, US.
2022. Risk-Adapted Treatment of Myelofibrosis: A Focus on Quality of Life. Conference. University of Alabama Medical Center, Birmingham, AL. Virtual, US.
2022. Risk-Adapted Treatment of Myelofibrosis: A Focus on Quality of Life. Conference. Sarah Cannon Cancer Center, Overland Park, KS. Virtual, US.
2022. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Conference. Aptitude Health. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Conference. Aptitude Health. Virtual, US.
2022. Updates in MPNs and Mastocytosis. Conference. The University of Alabama at Birmingham. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Conference. Aptitude Health. Virtual, US.
2022. Current Management and Emerging Challenges in MF. Conference. Aptitude Health. Virtual, US.
2021. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. North Florida/South Georgia VA Health System, Lake City, FL. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. University of Alabama Medical Center, Birmingham, AL. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. UT MD Anderson Cancer Center. Virtual, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. Northside Hospital, Lawrenceville, GA. Virtual, US.
2020. Managing Myelofibrosis: Writing the Next Chapter in the JAK inhibitor Story. Conference. Estate Restaurant and Bar. Santa Monica, CA, US.
2020. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. Webinar, US.
2019. Moving the Treatment of MPNs Forward: Integration of Recent Data Sets Into Clinical Practice. Conference. Cape Fear Valley Medical Center. Fayettville, NC, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions: An Oncology Exchange Initiative. Conference. Union Hospital. Terre Haute, IN, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions: An Oncology Exchange Initiative. Conference. Cancer Treatment Centers of America. Goodyear, AZ, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Conference. Memorial Healthcare System. Miami, FL, US.
2019. What is new in ET, PV and MF?. Conference. Oncology Meeting Innovations (DAVA Oncology). Seattle, WA, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Conference. Halifax Health. Daytona Beach, FL, US.
2019. Recent Updates in the Diagnosis and Prognosis of Myelofibrosis. Conference. Oncology Nursing Society (Treasure Coast chapter). Sebastian, FL, US.
2019. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Conference. Oncology Nursing Society (Treasure Coast chapter). Sebastian, FL, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Conference. University Medical Center of Southern Nevada. Las Vegas, NV, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Conference. Northwestern Prentice Women’s Hospital. Chicago, IL, US.
2019. Treatment of Myelofibrosis and Other MPNs: Best Practices and Future Directions An Oncology Exchange Initiative. Conference. Potomac Center for Medical Education/Rockpointe Oncology. Salt Lake City, UT, US.
2018. Classic Philadelphia chromosome negative MPN. Conference. Local hematologists and hematopathologists. Kolkata, IN.
2018. Developmental Therapeutics in MPN. Conference. Oncology Meeting Innovations (DAVA Oncology). Seattle, WA, US.
2018. Developmental Therapeutics in MPN. Conference. Oncology Meeting Innovations (DAVA Oncology). Boston, MA, US.
2018. Understanding the Biological Complexity of Myeloproliferative Neoplasms. Conference. Oncology Nursing Society, northern Ohio chapter. Lima, OH, US.
2018. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Conference. Oncology Nursing Society, northern Ohio chapter. Lima, OH, US.
2018. Myelofibrosis and Polycythemia vera: Integrating Recent Advances Into Clinical Practice. Conference. VA Western NY Healthcare System. Buffalo, NY, US.
2018. Challenges in Diagnosis and Management of Essential Thrombocythemia. Conference. Oncology Nursing Society, Louisiana chapter. Mandeville, LA, US.
2018. Advances in Diagnosis, Prognosis and Therapy of Polycythemia Vera. Conference. Oncology Nursing Society, Louisiana chapter. Mandeville, LA, US.
2018. Myelofibrosis and Polycythemia Vera: Integrating Recent Advances Into Clinical Practice. Conference. Robert Wood Johnson Hamilton Hospital. Hamilton, NJ, US.
2018. Myelofibrosis and Polycythemia Vera: Integrating Recent Advances Into Clinical Practice. Conference. Thomas E. Creek VA Medical Center. Amarillo, TX, US.
2017. What is new in myeloproliferative neoplasms?. Conference. OMI (Dava Oncology). Pasadena, CA, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Conference. St. Mary's Hospital and Medical Center. Evansville, IN, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Conference. Holmes Regional Medical Center. Melbourne, FL, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Conference. Bayfront Health St Petersburg. St Petersburg, FL, US.
2016. Underdiagnosed & Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) & Myelofibrosis (MF). Conference. Western Maryland Regional Medical Center. Cumberland, MD, US.
2016. Management and Treatment of Polycythemia Vera. Conference. Quillen College of Medicine, East Tennessee State University. Johnson City, TN, US.
2015. 2015 Update on Chronic Lymphocytic Leukemia. Conference. North Carolina Oncology Association. Asheville, NC, US.
2015. 2015 update on CLL and MDS. Conference. Virginia Association of Hematologists and Oncologists. Hot Springs, VA, US.
2015. Myelodysplastic syndromes. Conference. Virginia Oncology Associates. Virginia Beach, VA, US.
2014. CLL, CML and MDS: where do we stand in 2014?. Conference. Virginia Association of Hematologists and Oncologists. Hot Springs, VA, US.
2013. Targeted therapies and rational combinations for the myeloid malignancies. Conference. VCU Massey Cancer Center. Richmond, VA, US.
2013. Concomitant HDAC and Wee1 inhibition in AML. Conference. Southeast Phase 2 Consortium. Clearwater Beach, FL, US.
2007. Pasteurella hemolytica: An unusual cause of osteomyelitis. Conference. American College of Physicians. Kalamazoo, MI, US.
2007. Legionnaire’s Disease: Ubiquitous But Under-recognized. Conference. American College of Physicians. East Lansing, MI, US.
2007. Hypokalemic Periodic Paralysis: Not Always Familial. Conference. American College of Physicians. East Lansing, MI, US.
2007. Hepatic presentation of primary(AL) amyloidosis. Conference. American College of Physicians. East Lansing, MI, US.
2006. Daptomycin-Induced Rhabdomyolysis. Conference. Society of General Internal Medicine. Chicago, IL, US.
2006. Strongyloidiasis following Autologous Stem Cell Transplantation (SCT) for Non Hodgkin’s Lymphoma (NHL) treated with Rituximab and Conventional Chemotherapy. Conference. American College of Physicians. Troy, MI, US.
2006. Gorham’s (Vanishing Bone) Disease: A Medical Mystery. Conference. American College of Physicians. Troy, MI, US.
2006. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. Conference. American College of Physicians. Troy, MI, US.
2005. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. Conference. Society of General Internal Medicine. Chicago, IL, US.

National Presentations

2024. Prefibrotic Myelofibrosis: Special considerations for a new entity. Invited. MPN Workshop of the Carolinas. Asheville, NC, US.
2024. Novel Mechanisms of Drug Action in MF. Invited. MD Education. La Jolla, CA, US.
2024. Current Treatment Strategies for Anemia of MF. Invited. GSK. La Jolla, CA, US.
2024. Current Therapy for Intermediate/High Risk Myelofibrosis. Invited. Physicians Education Resource. Miami Beach, FL, US.
2023. Evolving Strategies for the Management of Anemia in MF. Invited. Alpine Oncology Foundation. La Jolla, CA, US.
2023. Current Myelofibrosis Treatment Landscape. Invited. Medscape Oncology. San Diego, CA, US.
2023. Optimizing Clinical Decision-Making for Patients with MF. Invited. Research to Practice. Houston, TX, US.
2023. Current and Emerging Therapies for Systemic Mastocytosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2023. Current and Emerging Treatment Options for Patients with ET and PV. Conference. Curio Science National Summit. Marco Island, FL, US.
2023. Post Hoc Analyses and Indirect Comparisons Among JAK Inhibitors. Invited. Curio Science Congress Connect - Myelofibrosis: ASCO/EHA 2023. Virtual, US.
2023. VONJO (pacritinib) capsules. Part of "The role of VONJO (pacritinib) capsules in myelofibrosis". Invited. CTI BioPharma. Virtual, US.
2023. What to do When Blasts Increase in MPN. Invited. MD Education. Phoenix, AZ, US.
2023. Current treatment strategies for anemic MF patients and underlying gaps (part of “Understanding challenges and treatment options in the anemic Myelofibrosis (MF) patient”). Invited. MD Education. Phoenix, AZ, US.
2023. Progress in Polycythemia Vera. Invited. PER. Miami Beach, FL, US.
2022. Novel Therapies in MF as Single Agents Beyond JAKi: Importance of spleen volume and symptom burden reduction. Invited. MPN Controversies and Debates. Virtual, US.
2022. Myelofibrosis. Invited. Philippine College of Hematology and Blood Transfusion. Webinar, US.
2022. Management of Pre-Fibrotic Primary Myelofibrosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2022. Management of cytopenias in MF: an Emerging Area for Therapeutic Approaches and Drug Development. Invited. TX MPN Workshop. San Antonio, TX, US.
2022. Indolent Systemic Mastocytosis. Invited. "TeleEcho" program. Virtual, US.
2022. Status of Unmet Need in Cytopenic MF and Clinical Prognosis (as part of "Cytopenic MF: an Update"). Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Advanced Systemic Mastocytosis: State of the Art. Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Managing Anemia in the Era of JAK Inhibition (as part of "The Evolving Challenge of Anemia in Myelofibrosis"). Invited. US Focus on MPNs and MDS. San Diego, CA, US.
2022. Advanced Systemic Mastocytosis: Patient Quality Initiative. Invited. NCODA. Virtual, US.
2022. Myelofibrosis. Invited. Mumbai Hematology Group. Virtual (webinar), US.
2022. Essential Thrombocythemia. Invited. Clinical Care Options. Virtual, US.
2022. Key MPN Presentations from the 63rd (2021) American Society of Hematology (ASH) Annual Meeting. Invited. Research To Practice. Virtual, US.
2022. Improving Anemia in Myelofibrosis with Momelotinib. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. The Evolving Landscape in Systemic Mastocytosis: KIT and Beyond. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. "Disease Modification" in Myelofibrosis: An Elusive Goal?. Invited. DAVA Oncology (Oncology Meeting Innovations). Amelia Island, FL, US.
2022. Other JAK inhibitors and future treatments. As part of a Masterclass on CML and MPN. Invited. Turkish Hematology Academy. Virtual, US.
2021. Novel Therapies for Anemia in Myelofibrosis. Invited. Alpine Oncology Foundation (XVIth Annual Post-ASH MPN/CML Workshop). Virtual, US.
2021. A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis. Conference. American Society of Hematology. Atlanta (presented virtually), GA, US.
2021. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Conference. American Society of Hematology. Atlanta (presented virtually), GA, US.
2021. Polycythemia Vera and Essential Thrombocythemia. Invited. Mumbai Hematology Group. Virtual, US.
2021. Pelabresib. As part of Virtual Think Tank on Myelofibrosis Targeting Apoptosis, Telomerase and Epigenetics. Invited. DAVA Oncology (Oncology Meeting Innovations). Virtual, US.
2021. Emerging Approaches to Treating Cytopenic MF. As part of “Exploring New Approaches for Treating Patients with Cytopenic Myelofibrosis”. Invited. Medscape. Virtual, US.
2021. Pelabresib (CPI-0610) Improved Anemia Associated With Myelofibrosis: Interim Results From Ongoing MANIFEST Phase 2 Study. Conference. Society of Hematologic Oncology. Virtual, US.
2021. Indolent Systemic Mastocytosis. Invited. Texas MPN Workshop. Virtual, US.
2021. Systemic Mastocytosis Research at MDACC. Invited. American Initiative on Mast Cell Diseases. Virtual, US.
2021. Hydroxyurea-resistant polycythemia vera. As part of MPN Virtual Tumor Board. Invited. Targeted Oncology. Virtual, US.
2021. Survival in MF. As part of “Ruxolitinib – A Decade as Standard of Care for Myelofibrosis – Lessons Learned”. Invited. Incyte Corporation (Independent Satellite Sympoisum). Virtual, US.
2021. How do you manage treatment failure in myelofibrosis?: Failure due to cytopenias. Invited. BMS (Independent Satellite Symposium). Virtual.
2020. Update on avapritinib in advanced systemic mastocytosis. Invited. Alpine Oncology Foundation (XVth post-ASH CML/MPN workshop). Virtual, US.
2020. Sotatercept (ACE-011) for Anemia of Myelofibrosis. Conference. American Society of Hematology. Virtual, US.
2020. Understanding the Evolving Treatment Landscape of Polycythemia Vera. Invited. Physicians' Education Resource. Virtual, US.
2020. Management of side effects and loss of response to ruxolitinib. Invited. MD Education. Virtual, US.
2020. Optimizing JAK inhibition in myelofibrosis. Invited. Incyte Corporation. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. Next questions: Myeloproliferative Neoplasms. Invited. Society of Hematologic Oncology. Virtual, US.
2020. A young woman with thrombocytosis. Invited. Society of Hematologic Oncology. Virtual, US.
2020. ET: Disease outcomes, unmet needs and therapeutic strategies. Invited. Texas MPN Workshop. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. Advances in Polycythemia Vera: Managing Patients in 2020. Invited. Total CME. Virtual, US.
2020. MPN Transition from Chronic to Blast Phase MPN. Invited. Targeted Oncology. Virtual, US.
2020. Ruxolitinib-based Combination Therapies for Myelofibrosis. Invited. ALMPN Expert Forum. Dallas, TX, US.
2020. Navigating the Treatment Landscape in MF: Risk-Adapted Therapy and the New JAK Inhibitor Era. Invited. PeerView. Orlando, FL, US.
2019. Activin Receptor Ligand Traps and the way forward with targeting TGF-β in MF. Invited. Alpine Oncology Foundation. Orlando, FL, US.
2019. Emerging Treatment Options for MPNs. Invited. Medscape. Orlando, FL, US.
2019. Identifying and Treating “Progression” in Myelofibrosis. Invited. Society of Hematologic Oncology. Houston, TX, US.
2019. Preference categorization of therapies for advanced systemic mastocytosis. Invited. National Comprehensive Cancer Network. Plymouth Meeting, PA, US.
2019. Emerging Therapies in Myeloproliferative Neoplasms. Invited. Curio Science - Vaniam Group. Miami, FL, US.
2018. Ruxolitinib-based combinations in myelofibrosis: past, present and future. Invited. Alpine Oncology Foundation. San Diego, CA, US.
2018. Polycythemia Vera. Invited. Incyte Corporation. Atlanta, GA, US.
2018. Emerging agents in myelofibrosis. Invited. 4th Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2018. Prognostic implications of recent advances in genomics in MPN. Invited. 4th Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2017. ET: unresolved questions and unmet needs. Invited. Alpine Oncology Foundation. Atlanta, GA, US.
2017. A PK/PD pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients with Myelofibrosis. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Sotatercept Alone and with Ruxolitinib in Patients with MPN-associated Myelofibrosis and Anemia. Conference. American Society of Hematology. Atlanta, GA, US.
2017. Myelofibrosis with cytopenias. Invited. Society of Hematologic Oncology. Houston, TX, US.
2017. Ruxolitinib: what are the successes and challenges in MPN?. Invited. 3rd Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX, US.
2016. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Conference. American Society of Hematology. San Diego, CA, US.
2016. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Conference. American Society of Hematology. San Diego, CA, US.
2013. AML: Current concepts, recent advances and future directions. Invited. OMICS Group. Raleigh, NC, US.
2008. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Conference. American Society of Hematology. San Francisco, CA, US.
2006. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. Conference. Society of General Internal Medicine. Los Angeles, CA, US.
2006. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. Conference. Society of General Internal Medicine. Los Angeles, CA, US.
Management of Anemia in Myelofibrosis (part of 2023 MPN Clinical Roadmap). Invited. MD Education. Virtual, US.
Individualizing Treatment for Patients With Myeloproliferative Neoplasms. Invited. Clinical Care Options (Clinical Education Alliance). Virtual, US.

International Presentations

2024. Current Treatment Options for Patients with Myelofibrosis who have Anemia. Invited. GSK. Madrid, ES.
2024. Selecting Initial Treatment for Patients with Myelofibrosis. Invited. Clinical Care Options. Chicago, US.
2024. Novel Therapies for High Risk MPN. Invited. European School of Hematology. Mandelieu La Napoule, FR.
2024. Cutting Edge Treatment Strategy for PV based on Real World Besremi experiences. Invited. Pharma Essentia. Virtual, JP.
2024. Clinical Experience with Ropeginterferon alfa-2b for the Treatment of Polycythemia Vera in the United States. Invited. MPN Asia 2024. Osaka, JP.
2024. Diagnosis and management of systemic mastocytosis: what's new in 2024?. Invited. International Academy of Clinical Hematology (IACH). Virtual, US.
2023. Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study. Conference. European Hematology Association. Frankfurt, DE.
2023. Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). Conference. European Hematology Association. Frankfurt, DE.
2023. A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS. Conference. European Hematology Association. Frankfurt, DE.
2023. UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS. Conference. European Hematology Association. Frankfurt, DE.
2023. Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias. Conference. American Society of Clinical Oncology. Chicago, US.
2023. Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF). Conference. American Society of Clinical Oncology. Chicago, US.
2023. Risk stratification in Myelofibrosis: Identifying Myelofibrosis patients for Stem Cell Transplant. Invited. Novartis. Buenos Aires (Virtual Speaker), AR.
2023. Treatment of Myelofibrosis in non-transplant candidates. Invited. Novartis. Buenos Aires (Virtual Speaker), AR.
2023. Ruxolitinib in Myelofibrosis and Polycythemia Vera. Invited. Novartis. Medellin, CO.
2022. Avapritinib in Advanced Systemic Mastocytosis. Conference. Blueprint Medicines Corporation. New York City, US.
2021. Case #4: Post-PV MF after Failure on Ruxolitinib. As part of “Providing Patient-Centric Care in MDS and MPNs: Improving Outcomes and Quality of Life With New Therapeutic Options”. Invited. Physicians' Education Resource. Virtual, US.
2021. Current Therapies and Clinical Advances in Myelofibrosis. As part of "Providing Patient-Centric Care in MDS and MPNs: Improving Outcomes and Quality of Life With New Therapeutic Options”. Invited. Physicians' Education Resource. Virtual, US.
2020. A 55-year-old Patient with PV Resistant to Hydroxyurea. Invited. Medicom Worldwide. Virtual, US.
2020. Exploring Evidence-Based Approaches in MF: The Latest on Approved and Emerging Options. Invited. PeerView. Virtual, US.
2019. Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): An open-label, prospective study. Conference. 9th Trends in Medical Mycology Conference. Nice, FR.
2019. Interactive Case Studies: Treatment Decisions after JAK inhibitor “Failure”. Invited. Medicom Worldwide. Houston, US.
2019. Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia. Conference. European Hematology Association. Amsterdam, NL.
2019. Early Results of a Phase II study of combined Ruxolitinib and Thalidomide in patients with Myelofibrosis. Conference. European Hematology Association. Amsterdam, NL.
2019. Phase 1/2 study of Ruxolitinib (RUX) Plus Decitabine (DAC) in Patients (pts) With Post-MPN AML. Conference. European Hematology Association. Amsterdam, NL.
2019. Characterizing Myelofibrosis for a Risk-Adapted Approach to Management in the JAK Inhibitor Era. Invited. PeerView. Chicago, US.
2019. Take home messages: MPN. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2019. Prognostication in myelofibrosis: state of the art. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2019. Prognostication and thrombotic risk stratification of PV/ET in the genomic era. Invited. Associacion Colombiana De Hematologia Oncologia. Bogota, CO.
2018. Current understanding of who responds to (needs) JAK2 inhibition in MPN. Invited. 5th Annual Summit on Hematologic Malignancies. Whistler, CA.
2017. Mutational Landscape of MDS/MPN-U. Conference. European Hematology Association. Madrid, ES.
2007. Hypokalemic Periodic Paralysis: Not Always Familial. Conference. Society of General Internal Medicine. Toronto, CA.
2007. Daptomycin-Induced Rhabdomyolysis. Conference. Society of General Internal Medicine. Toronto, CA.
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response. Invited. Medicom Worldwide. Virtual, US.
Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies. Invited. Medicom Worldwide. Virtual, US.

Formal Peers

2024. An Overview of the Classic Myeloproliferative Neoplams. Visiting. Global Academic Programs, UT MDACC. Houston, TX, US.
2023. MF Updates from ASCO/EHA 2023. Invited. Sumitomo Pharma America. Virtual, US.
2023. A Review of the Classic Myeloproliferative Neoplasms. Invited. Baylor College of Medicine. Houston (Virtual Speaker), TX, US.
2022. Emerging and Future Treatments for Myelofibrosis. Invited. Glaxo Smithkline. Dallas, TX, US.
2022. Myelofibrosis. Invited. Glaxo Smithkline. Dallas, TX, US.
2022. State of the Art Update on Polycythemia Vera. Invited. Pharma Essentia. Virtual, US.
2021. Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610): ASH 2021 Clinical Updates from Arms 2 and 1. Invited. Constellation Pharmaceuticals (now Morphosys). Virtual, US.
2021. Anemia in Myelofibrosis & Prior Momelotinib Data in Anemic MF Patients. As part of “Review of Momelotinib for the Potential Treatment of Myelofibrosis”. Invited. Sierra Oncology. Virtual, US.
2021. Current Topics in MPNs. Keynote lecture at Incyte Jakafi® Virtual Speaker Training Meeting. Invited. Incyte Corporation. Virtual, US.
2021. Optimizing JAK inhibition and moving beyond JAK inhibitors in myelofibrosis. Invited. The University of Oklahoma Health Sciences Center. Virtual, US.
2020. Beyond ruxolitinib: Novel agents and combinations for myelofibrosis. Invited. Houston Methodist Hospital. Houston, TX, US.
2020. Classic Myeloproliferative Neoplasms: An Update from ASH 2019. Invited. Morristown Medical Center. Morristown, NJ, US.
2019. Myelofibrosis Clinical Cases. Invited. Celgene Corporation (now BMS). Orlando, FL, US.
2019. Classic MPN. Invited. Baylor College of Medicine. Houston, TX, US.
2018. Treatment options for refractory CLL: new and novel small molecule inhibitors. Visiting. Global Academic Programs, UT MDACC. Houston, TX, US.
2018. Classic MPN. Invited. Baylor College of Medicine. Houston, TX, US.
2018. Emerging Data in MPNs. Invited. Incyte Corporation. Chicago, IL, US.
2018. Myelofibrosis. Invited. Baylor College of Medicine. Houston, TX, US.
2017. Treatment options for refractory CLL: new and novel small molecule inhibitors. Visiting. Global Academic Programs, UT MDACC. Houston, TX, US.
2017. The JAK-STAT pathway and cyclin-dependent kinases: an overview. Visiting. UT Health/UT MDACC Graduate School of Biomedical Sciences. Houston, TX, US.
2017. MOST Study Rationale. Invited. Incyte Corporation. Phoenix, AZ, US.
2013. Tumor Lysis Syndrome. Invited. Sanofi US. Las Vegas, NV, US.

Less

Grant & Contract Support

Date:	2023 - 2024
Title:	2022-0955-4362 - A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Funding Source:	Sumitomo Dainippon Pharma Oncology, Inc
Role:	PI
ID:	BBI-TP-3654-102

Date:	2023 - 2026
Title:	2022-0745 - A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Funding Source:	Janssen Pharmaceuticals
Role:	PI

Date:	2022 - 2027
Title:	2022-0291 - A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability of DISC-0974 in Subjects with Myelofibrosis and Anemia
Funding Source:	Disc Medicine
Role:	PI
ID:	DISC-09714-102

Date:	2022 - 2027
Title:	2022-0183 - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects with MF who have a Suboptimal Response to Ruxolitinib
Funding Source:	Telios Pharma
Role:	PI
ID:	TL-895-209

Date:	2022 - 2027
Title:	2022-0072 - A Randomized, Double-Blind, Placebo- Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Funding Source:	Blueprint Medicines Corporation
Role:	PI
ID:	BLU-263-1201

Date:	2022 - 2029
Title:	2021-0897: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
Funding Source:	Ionis Pharmaceuticals
Role:	PI
ID:	AWD00006708

Date:	2022 - 2029
Title:	2021-1092-A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Funding Source:	Incyte Corporation
Role:	PI
ID:	2021-1092

Date:	2022 - 2029
Title:	2021-0880 (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS CGT9486-21-202
Funding Source:	Cogent Biosciences
Role:	PI
ID:	2021-0880

Date:	2021 - 2028
Title:	2020-1010 - A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on concomitant JAK2 Inhibitor Therapy and Who Require red Blood Cell Transfusions
Funding Source:	Celgene
Role:	Principal Investigator-MDACC

Date:	2021 - 2028
Title:	2020-1141- A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Funding Source:	Geron Corporation
Role:	Principal Investigator-MDACC

Date:	2021 - 2028
Title:	2021-0587 A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Funding Source:	Cogent Biosciences
Role:	PI
ID:	2021-0587

Date:	2021 - 2026
Title:	2021-0331 BLU-285-2203 - A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Funding Source:	Blueprint Medicine
Role:	PI
ID:	2021-0332

Date:	2021 - 2022
Title:	Molecular Basis and Preclinical Efficacy of targeting LSD1 (KDM1A) in post-MPN secondary AML
Funding Source:	MD Anderson
Role:	Investigator
ID:	RCTS#2021-0060087-Y1

Date:	2021 - 2026
Title:	2020-0739 - A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Funding Source:	Constellation Pharmaceuticals
Role:	Principal Investigator-MDACC

Date:	2020 - 2027
Title:	2020-0522_"A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis"
Funding Source:	Bristol-Myers Squibb
Role:	PI
ID:	2020-0522

Date:	2020 - 2025
Title:	2020-0409 - A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Funding Source:	Incyte Corporation
Role:	Principal Investigator-MDACC

Date:	2020 - 2024
Title:	2020-0279_An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2020-0279

Date:	2019 - 2024
Title:	2018-0943_An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Funding Source:	Blueprint Medicines
Role:	PI
ID:	2018-0943

Date:	2019 - 2020
Title:	2018-0907_A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2018-0907

Date:	2019 - 2023
Title:	2018-0906_An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Funding Source:	Kartos Therapeutics
Role:	PI
ID:	2018-0906

Date:	2018 - 2023
Title:	2018-0202_A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Funding Source:	Constellation Pharmaceuticals, Inc
Role:	PI
ID:	2018-0202

Date:	2018 - 2021
Title:	2018-0022_An Open-Label, Multi-center, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Funding Source:	Incyte Corporation
Role:	PI
ID:	2018-0022

Date:	2018 - 2021
Title:	2017-0504_A phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept (ACE-536) in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia with and without red blood cell-transfusion dependence
Funding Source:	Celgene Corporation
Role:	PI
ID:	2017-0504

Date:	2017 - 2020
Title:	2017-0512_EVALUATION OF RUXOLITINIB and THALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	PI
ID:	2017-0512

Date:	2017 - 2021
Title:	2017-0320_An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Funding Source:	CTI BioPharma
Role:	PI
ID:	2017-0320

Date:	2017 - 2019
Title:	2016-0373_A Phase II study of isavuconazole prophylaxis in adult patients with AML/MDS and neutropenia
Funding Source:	Astellas Pharma
Role:	PI
ID:	2016-0373

Date:	2017 - 2019
Title:	2017-0111_A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
Funding Source:	Incyte Corporation
Role:	PI
ID:	2017-0111

Date:	2016 - 2019
Title:	2015-0832_A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Funding Source:	Blueprint Medicines Corporation
Role:	PI
ID:	2015-0832

Date:	2015 - 2019
Title:	2015-0787_Alternating or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Funding Source:	Pfizer
Role:	PI
ID:	2015-0787

Date:	2013 - 2020
Title:	2013-0051_A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
Funding Source:	Promedior
Role:	PI
ID:	2013-0051

Date:	2012 - 2022
Title:	2012-0534_A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA
Funding Source:	Celgene
Role:	PI
ID:	2012-0534

Date:	2011 - 2021
Title:	2011-0090_A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
Funding Source:	NS Pharma
Role:	PI
ID:	2011-0090

CV information above last modified April 16, 2025

Prithviraj Bose, M.D.

About Dr. Bose

In the News

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Prithviraj Bose, M.D.

About Dr. Bose

In the News

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer